BLUE:NSD-bluebird bio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.24

Change

0.00 (0.00)%

Market Cap

USD 0.51B

Volume

0.01B

Avg Analyst Target

USD 14.50 (+100.28%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


bluebird bio Inc (BLUE) Stock Analysis:
Based on the bluebird bio Inc stock forecasts from 13 analysts, the average analyst target price for bluebird bio Inc is USD 14.50 over the next 12 months. bluebird bio Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of bluebird bio Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, bluebird bio Inc’s stock price was USD 7.24. bluebird bio Inc’s stock price has changed by -1.49% over the past week, -4.16% over the past month and -84.48% over the last year.

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-depende ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

USD25.75B N/A N/A
SGEN Seagen Inc

N/A

USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

USD16.81B 20.32 11.89

ETFs Containing BLUE

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

N/A

USD0.04B
DRUP:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

N/A

USD0.23B
BBIG:CA Horizons Global BBIG Tech.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.53% 24% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.53% 24% F 13% F
Trailing 12 Months  
Capital Gain -84.48% 8% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.48% 8% F 4% F
Trailing 5 Years  
Capital Gain -89.29% 19% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.29% 19% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -19.53% 12% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.53% 12% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 57.18% 52% F 29% F
Risk Adjusted Return -34.16% 19% F 10% F
Market Capitalization 0.51B 68% D+ 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.72 95% A 94% A
Price / Cash Flow Ratio -1.08 15% F 56% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.21% 38% F 15% F
Return on Invested Capital -47.74% 50% F 18% F
Return on Assets -32.67% 34% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.24 61% D- 51% F
Short Percent 10.37% 17% F 16% F
Beta 1.61 30% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.